Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.62 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299391 | 0.84 | F10 (0.64) | F10ATMMAPT | |
| SCHEMBL6807951 | 0.83 | F10 (0.80) | F10ATM | |
| SCHEMBL5733762 | 0.81 | F10 (0.72) | F10ATML3MBTL1 | |
| SCHEMBL5734081 | 0.81 | F10 (0.67) | F10ATML3MBTL1 | |
| SCHEMBL6730044 | 0.81 | F10 (0.69) | F10ATMMAPT | |
| SCHEMBL6301332 | 0.79 | F10 (0.67) | F10ATMMAPT | |
| SCHEMBL6299384 | 0.79 | F10 (0.66) | F10ATM | |
| SCHEMBL6300303 | 0.78 | F10 (0.68) | F10ATMMAPT | |
| SCHEMBL6304930 | 0.78 | F10 (0.69) | F10ATMMAPT | |
| SCHEMBL6306256 | 0.77 | F10 (0.67) | F10SLC6A7ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | MILENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1322610-A2 | PIPERAZINE BASED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026720-A2 | PIPERAZINE BASED INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | TFPI, F11, F12 | F10 11/4885SLC6A7 897/4885ATM 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.